Special Issue

Smart Radiotherapy Biomaterials for Cancer Therapy and Imaging

Message from the Guest Editors

Cancer is the second cause of death worldwide in 2024, and one of the main reasons for its poor therapy is due to traditional treatment modalities such as chemotherapy, radiotherapy, and/or surgery. The associated toxicity related to the traditional treatment methods elicits many studies to be conducted preclinically evaluating the use of smart radiotherapy biomaterials in cancer treatment. The acclimation of smart biomaterials to the fluctuating physiological parameters and any outward tensions makes them compelling influencers on many aspects of homeopathic technology. Smart biomaterials can enhance promising treatments and boost the administration of long-lasting diseases, and they are applied in the fields of drug delivery systems, regenerative medicine, radiotherapy, medical gadgets, and immunotherapy. Preclinical studies have demonstrated many advantages, such as active targeting, long circulation, low immunogenicity, controlled drug release, and reduced toxicological effects in utilizing nanocarriers as targeted therapy for malignant tumors. Smart biomaterials can offer tissuedemonstrated precise modulation in the immunity of a cancer patient.

Guest Editors

Dr. Kai Ding

Dr. Michele Moreau

Dr. Debarghya China

Deadline for manuscript submissions

10 December 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/214695

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

